"Everything we have seen to date suggests that NOX66 in...

"Everything we have seen to date suggests that NOX66 in combination with radiotherapy will be our path to market. But until we know that for certain, it's important that we give ourselves the best chance of picking the winner. Hence the three-horse race.

And come the end of this year, we have to be in the position where we can pick the best candidate to take into a registration study in 2019."

"Moving towards first registration
Likely registration indication: NOX66 in combination with palliative external beam radiotherapy for the treatment of patients with metastatic cancer (prostate and others)"http://imagesignal.commsec.com.au/d...nZXNpZ25hbC9lcnJvcnBhZ2VzL3BkZmRlbGF5ZWQuanNw

DART and LUPIN are both booked in for phase two studies in 2019 and then to registration. What is missing from this presentation is the first hint from management that CEP wont make 2/3Phase study.

Read between the lines. It is hard with NOX but it is there. But they have already in their CORPORATE PRESENTATION: POSTINTERIM CLINICAL DATA RELEASE told investor the likely outcome. In others word picking the best horse for registration....well that have already hinted at and published that is most likely not going to be CEP. But hey we don't know for certain......